Extracellular vesicles from prostate tumors reshape the pre-metastatic bone environment in an mTOR/RAB1A-dependent manner
BackgroundBone is the most common metastatic site in prostate cancer (PCa) patients and serves as a key contributing factor to the poor prognosis observed in advanced-stage patients. Mammalian target of rapamycin (mTOR) inhibition has limited clinical …